Clinical trials: Placebo-Post
Moderate to Severe Acute Postoperative Pain
Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.
- Trial name
- NCT07147049
- Testing
- HL-1186
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Pain, Postoperative, Bunion
Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension
The primary objective of this study is to show the effectiveness of repeated doses of COV795 versus placebo, using the summed pain intensity difference over the first 48 hours in subjects with acute moderate to severe pain…
- Trial name
- NCT01484652
- Testing
- COV795
- Where
- 5 sites in United States
- Volunteers
- 329 people
- Sponsor
- Mallinckrodt
Hernia, Inguinal, Post Operative Pain
Herniorrhaphy for Postoperative Pain
Subjects receive either CPL-01, positive control, or negative control after herniorrhaphy and are then followed.
- Trial name
- NCT05813847
- Testing
- local anaesthetic injection of CPL-01, Morphine (rescue medication), Acetaminophen (rescue medication)
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- Cali Pharmaceuticals LLC
Post-operative Pain
Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
The objective is to assess the efficacy and tolerability of a combination of 400 mg ibuprofen plus 1000 mg acetaminophen, 200 mg ibuprofen plus 500 mg acetaminophen compared with Nurofen Plus® and Panadeine® Extra.
- Trial name
- NCT01229449
- Testing
- Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®
- Where
- United States
- Volunteers
- 678 people
- Sponsor
- Reckitt Benckiser LLC
COPD
Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
The study is performed to investigate the effect of the spacing device on the pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without Aerochamber Plus Flow-vu antistatic VHC spacer as a single…
- Trial name
- TRIPLE 4 (NCT02119234)
- Testing
- Beclometasone/formoterol/glycopyrrolate
- Where
- Poland
- Volunteers
- 36 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Healthy
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 first in human clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous…
- Trial name
- NCT05701644
- Testing
- C1K 150mg, C1K 300mg, C1K 600mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ensol Bioscience
Acute Pain
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute postoperative pain after bunionectomy.
- Trial name
- APOLLO-1 (NCT02815709)
- Testing
- Oliceridine, Morphine
- Where
- 7 sites in United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Trevena Inc.
Pain, Postoperative
Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty
The purpose of this phase 3 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections for treating post-operative pain following abdominoplasty.
- Trial name
- NCT03997838
- Testing
- VVZ-149 Injections
- Where
- 5 sites in United States
- Volunteers
- 307 people
- Sponsor
- Vivozon, Inc.
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Healthy Adult Subjects
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of ID110521156 in healthy adult subjects.
- Trial name
- NCT06635226
- Testing
- ID110521156
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Glioblastoma
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
This multicenter, double-blind, placebo-controlled, randomized study will evaluate the efficacy and safety of the addition of bevacizumab treatment to lomustine (in 2nd-line [2L] treatment) and SOC (in 3rd-line [3L] and…
- Trial name
- NCT01860638
- Testing
- Bevacizumab, Lomustine, Radiotherapy
- Where
- 64 sites in Austria, Bulgaria and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Post Traumatic Stress Disorder
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo…
- Trial name
- EMPOWER-2 (NCT07836647)
- Testing
- TSND-201
- Where
- 9 sites in United States
- Volunteers
- 300 people
- Sponsor
- Transcend Therapeutics
Major Depressive Disorder
6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
This is a 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder.
- Trial name
- NCT01145755
- Testing
- AZD2066, Duloxetine
- Where
- 13 sites in United States
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Carcinoma, Non Small Cell Lung
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic…
- Trial name
- VITAL (NCT00532155)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 913 people
- Sponsor
- Sanofi
PTSD
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
- Trial name
- NCT05181995
- Testing
- NYX-783
- Where
- 37 sites in United States
- Volunteers
- 121 people
- Sponsor
- Aptinyx
Friedreich's Ataxia
Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)
This is a Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study. The aim is to further investigate the effects of idebenone in patients with Friedreich's ataxia.
- Trial name
- PROTI (NCT01303406)
- Testing
- Idebenone
- Where
- 6 sites in Austria, Germany and 2 more
- Volunteers
- 29 people
- Sponsor
- Santhera Pharmaceuticals
Panic Disorder
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment
This study is designed to investigate if 600 mg ELB139 given orally t.i.d. to patients suffering from panic disorder is effective in reducing anxiety evoked by inhalation of 35% CO2 measured by a visual analogue scale after the…
- Trial name
- NCT00322803
- Testing
- ELB139
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 24 people
- Sponsor
- elbion AG
ST Segment Elevation Myocardial Infarction
NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction
This study will assess the safety and efficacy of intracoronary artery administered autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial infarction (STEMI).
- Trial name
- PreSERVE-AMI (NCT01495364)
- Testing
- NBS10
- Where
- 58 sites in United States
- Volunteers
- 195 people
- Sponsor
- Lisata Therapeutics, Inc.
Analgesia Disorder, Pain
A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management
This is a randomized, double blind, placebo-controlled, single dose study to assess the safety and efficacy of intramuscular sebacoyl dinalbuphine ester (SDE) for post-hemorrhoidectomy pain management.
- Trial name
- NCT02468128
- Testing
- Sebacoyl Dinalbuphine Ester
- Where
- 6 sites in Taiwan
- Volunteers
- 221 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.